search
Type 2 diabetes
Trends
- 1New tool predicts 31-day readmission risk in type 2 diabetes▼A nomogram incorporating nutritional risk for predicting 31-day unplanned readmission in adults with type 2 diabetes mellitus using LASSO regression
Researchers have developed a nomogram that combines nutritional risk screening with LASSO regression to predict the likelihood of unplanned readmission within 31 days for adults with type 2 diabetes. The tool is aimed at helping clinicians identify high-risk patients early and target follow-up care, with nutritional status highlighted as a key factor in hospital returns.
- 2Large genetic study probes type 2 diabetes in East Asian populations▼Decomposing population differences in type 2 diabetes through a high-resolution GWAS of ~600,000 individuals with East Asian ancestry
Researchers have published a high-resolution genome-wide association study of roughly 600,000 people with East Asian ancestry, aiming to decompose population-level differences in type 2 diabetes risk. The work, appearing in Nature, identifies ancestry-specific genetic factors that may explain why diabetes patterns differ between East Asian and European populations, with potential implications for risk prediction and treatment across populations.
- 3Oral GLP-1 pill safiglipron shows promise in early type 2 diabetes trial▼Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial
A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.